2m 2m 2m 2m 2m 2m 2m
- $260.1MMarket Cap
- -30.14%1-Year Change
- Medical DevicesIndustry
TREACE MED CNCPT (TMCI)
Key Performance
More- Earnings Score: N/A
- Momentum Score: 49
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Law firm Johnson Fistel is investigating potential securities fraud and breaches of fiduciary duties for four publicly traded companies, alleging false statements, misleading disclosures, and operational misrepresentations.
12/01/2025, 5:44 PM • GlobeNewswire
Grabar Law Office is investigating potential shareholder claims against four companies, alleging various corporate misconduct including false financial statements, misleading disclosures, and potential breaches of fiduciary duties.
09/26/2025, 9:04 AM • Benzinga
Treace Medical (TMCI) Q2 Revenue Up 7%
Treace Medical Concepts reported Q2 2025 earnings with a 7% revenue increase, narrowing net losses and expanding its bunion correction product portfolio. The company maintained its full-year revenue guidance and aims to target more bunion procedure markets.
08/07/2025, 10:20 PM • The Motley Fool
Grabar Law Office is investigating potential securities fraud and fiduciary breaches for several publicly traded companies, alleging misleading statements, financial misrepresentations, and operational issues that impacted investor confidence.
07/10/2025, 5:31 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Key Executives
- John T. Treace
- Mark L. Hair
- Brad Barr
- Sean F. Scanlan
- Scot Elder
Current Ownership Distribution
- Institutions484.9M (74.02%)
- Mutual Funds151.9M (23.19%)
- Insiders18.3M (2.80%)
- Other0 (0.00%)